Today in Drug Research

Drug Research

Seattle Genetics to buy Cascadian Therapeutics for $614m Seattle Genetics has agreed to acquire Cascadian Therapeutics, a clinical-stage biopharmaceutical company engaged in the development of product candidates for the treatment of cancer, for around $614m. Drug Research > Drug Discovery & Development > News

Latest Drug Research News by Sector

Select a sector from the list or browse by sector below:

Drug Delivery

Mundipharma agrees to distribute Grünenthal's pain-relief drug in China
Mundipharma has agreed to market and distribute Grünenthal’s Tramal (tramadol) in China from 1 May 2018.
Drug Research > Drug Delivery > News
e-Therapeutics signs two collaboration deals to enhance AI technology capabilities
By PBR Staff Writer
UK-based drug developer e-Therapeutics has agreed to collaborate with Intellegens and Biorelate to improve and extend its artificial intelligence (AI) technology capabilities.
Drug Research > Drug Delivery > News

Drug Discovery & Development

Veloxis secures $60m capital from Athyrium Capital
Veloxis Pharmaceuticals has secured $60m of capital from funds managed by Athyrium Capital Management, a healthcare-focused investment firm.
Drug Research > Drug Discovery & Development > News
Astellas Pharma acquires Universal Cells for $102m
Astellas Pharma has acquired Universal Cells for $102.5m in a move to utilize the latter’s technology to produce pluripotent stem cells that have the potential to lower immunological rejection in various therapeutic areas.
Drug Research > Drug Discovery & Development > News